You are here

Evaluate The Clinical Effectiveness, Safety And Tolerability Of Sildenafil Used In Doses ≥20mg TID For The Treatment Of Pulmonary Arterial Hypertension

Last updated on March 30, 2020

FOR MORE INFORMATION
Study Location
Medizinische Hochschule Hannover
Hannover, , 30625 Germany
Contact
1-800-718-1021
Eligibility criteria
Condition
The disease, disorder, syndrome, illness, or injury that is being studied.
Pulmonary Arterial Hypertension
Sex
Females and Males
Age
Pediatric Trials: 0-17 Years
Adult Trials: 18+ Years
18 + years
Inclusion criteria
The factors, or reasons, that allow a person to participate in a clinical study.
Show details

- Patients must be at least 18 years of age at study index;

- Patients must have a diagnosis of PAH. PAH is conventionally defined as a mean
pulmonary arterial pressure (PAP) of > 25 mmHg and a pulmonary capillary wedge
pressure (PCWP) ≤ 15 mmHg and a pulmonary vascular resistance (PVR) ≥ 240 dynes/s/cm-5
at right heart catheterization;

- Patients must have initiated sildenafil for the treatment of their PAH; at dose ≥ 20
mg tid within 5 years prior to study initiation

Exclusion criteria
The factors, or reasons, that prevent a person from participating in a clinical study.
Show details

- Patient has known contraindications to sildenafil at study index;

- Patient participated in an investigational study of sildenafil treatment for PAH
during the period beginning 6 months prior to study index

NCT01365585
Pfizer
Completed
Evaluate The Clinical Effectiveness, Safety And Tolerability Of Sildenafil Used In Doses ≥20mg TID For The Treatment Of Pulmonary Arterial Hypertension

NEED INFO?

Questions about a trial? Call or email to reach a Pfizer Clinical Trial Contact Center Representative

Pfizer Clinical Trials Contact Center

1-800-718-1021

[email protected]

call now

Try a new search

Search for Clinical Trials by condition, keyword or trial number. Share your location or enter your city or zip code to find studies near you.

Based on your search, you may also be interested in

Pulmonary Arterial Hypertension
NCT03364244
All Genders
0+
Years
Tokyo,
Pulmonary Arterial Hypertension
NCT02060487
All Genders
18+
Years
Multiple Sites
Descriptive Information
Brief Title Evaluate The Clinical Effectiveness, Safety And Tolerability Of Sildenafil Used In Doses ?20mg TID For The Treatment Of Pulmonary Arterial Hypertension
Official Title Evaluate The Clinical Effectiveness, Safety And Tolerability Of Sildenafil Used In Doses ?20mg TID For The Treatment Of Pulmonary Arterial Hypertension
Brief Summary The objective of this observational study is to gain clinical insight on the actual use of sildenafil citrate (Revatio?) for the treatment of pulmonary arterial hypertension (PAH). The primary objective is to assess effectiveness and safety of sildenafil at doses ?20mg three times daily for the treatment of PAH.
Detailed Description The study design proposed is a retrospective chart review going back five years (01 April 2006 estimate) from the time of study initiation (31 March 2011 estimate). Within this five-year period, study index will occur the first time an adult patient begins sildenafil for the treatment of PAH for a period of at least three months. The patient has to be taking sildenafil at doses ? 20mg tid for the treatment of PAH.
Study Type Observational
Study Design Observational Model: Cohort
Time Perspective: Retrospective
Target Follow-Up Duration Not Provided
Biospecimen Not Provided
Sampling Method Non-Probability Sample
Study Population Patients at least 18 years of age diagnosed with pulmonary arterial hypertension (PAH; per Dana Point classification) and treated with sildenafil citrate for their PAH
Condition Pulmonary Arterial Hypertension
Intervention Drug: sildenafil citrate
Sildenafil citrate, 20mg oral tablets, taken at least three times daily
Study Groups/Cohorts Sildenafil ?20mg three times daily
Subjects receiving sildenafil ?20mg three times daily for the treatment of PAH
Intervention: Drug: sildenafil citrate
Publications * Not Provided


*   Includes publications given by the data provider as well as publications
identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruitment Information
Recruitment Status Completed
Actual Enrollment
 (submitted: January 8, 2013)
227
Original Estimated Enrollment
 (submitted: June 1, 2011)
400
Actual Study Completion Date October 2011
Actual Primary Completion Date October 2011   (Final data collection date for primary outcome measure)
Eligibility Criteria

Inclusion Criteria:

  • Patients must be at least 18 years of age at study index;
  • Patients must have a diagnosis of PAH. PAH is conventionally defined as a mean pulmonary arterial pressure (PAP) of > 25 mmHg and a pulmonary capillary wedge pressure (PCWP) ? 15 mmHg and a pulmonary vascular resistance (PVR) ? 240 dynes/s/cm-5 at right heart catheterization;
  • Patients must have initiated sildenafil for the treatment of their PAH; at dose ? 20 mg tid within 5 years prior to study initiation

Exclusion Criteria:

  • Patient has known contraindications to sildenafil at study index;
  • Patient participated in an investigational study of sildenafil treatment for PAH during the period beginning 6 months prior to study index
Sex/Gender
Sexes Eligible for Study: All
Ages 18 Years and older   (Adult, Older Adult)
Accepts Healthy Volunteers No
Contacts Contact information is only displayed when the study is recruiting subjects
Listed Location Countries Germany,   Ireland
Removed Location Countries  
 
Administrative Information
NCT Number NCT01365585
Other Study ID Numbers A1481297
Has Data Monitoring Committee No
U.S. FDA-regulated Product Not Provided
IPD Sharing Statement Not Provided
Responsible Party Pfizer
Study Sponsor Pfizer
Collaborators Not Provided
Investigators
Study Director: Pfizer CT.gov Call Center Pfizer
PRS Account Pfizer
Verification Date March 2017

FOR MORE INFORMATION

Contact a representative by phone, email, or visiting the study website. Please see the references below:

BY PHONE

Pfizer Clinical Trials Contact Center

1-800-718-1021

BY EMAIL

Contact

[email protected]

Call Now